Abstract:OBJECTIVE:To evaluate the clinical efficacy and safety of huperzine Alpha in treatment of patients with mild to moderate Alzheimer disease (AD).METHODS:Two hundred and two patients with the diagnosis of possible or probable AD from 15 centers the nationwide were randomly divided into two groups: huperzine Alpha group (n = 100, given huperzine Alpha 400 micro g/day for 12 weeks) and placebo group (n = 102 ). Different scales were used to evaluate the cognitive function, activity of daily life (ADL), non-cognitive disorders, and overall clinical efficacy. Safety evaluation was conducted every 6 weeks.RESULTS:In comparison with the baseline data, there was an improvement of 4.6 points in cognition assessed by ADAS-Cog (P = 0.000); an improvement of 2.7 points by MMSE (P = 0.000), an improvement of 1.5 points in behavior and mood by ADAS-non-Cog (P = 0.008) with 59.2% of the patients being on the mend clinically; and an improvement of 2.4 points by ADL (P = 0.001) with the capacity of ADL improved by at least 10% among 32.75% of the patients. 70% of the patients in huperzine Alpha group scored 1 approximately 3 points, and 27.8% of them scored 1 approximately 2 points by CIBIC-plus. The proportions of patients with an improvement of >/= 4 points by ADAS-Cog were 56.1% and 12.5% in the huperzine Alpha group and placebo group respectively (P = 0.000). The proportions of patients with an improvement of >/= 4 points by MMSE were 37.8% and 10.1% in the huperzine Alpha group and placebo group respectively (P = 0.000). The proportions of patients with an improvement of 1 approximately 3 points in global rating by CIBIC-plus were 59.2% and 40.6% in the huperzine Alpha group and placebo group respectively (P = 0.01). The proportions of patients with an improvement of >/= 10% points by ADL were 32.7% and 17.2% in the huperzine Alpha group and placebo group respectively (P = 0.01). The proportions of patients with an improvement of > 0 points by ADS-non-C0g were 70.0% and 36.3% in the huperzine Alpha group and placebo group respectively (P = 0.000). Mild and transient adverse events (edema of bilateral ankles and insomnia) were observed in 3% of huperzine Alpha treated patients.CONCLUSION:A safe and effective medicine, huperzine Alpha remarkably improves the cognition, behavior, ADL,and mood of AD patients.

The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews

Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis

Huperzine A for Mild Cognitive Impairment.

Meta-analysis of Efficacy and Safety of Huperzine A for Mild and Moderate Alzheimer Disease

Adjunctive Huperzine A for Cognitive Deficits in Schizophrenia: a Systematic Review and Meta-Analysis

Huperzine A for Vascular Dementia.

O4‐04–06: Huperzine A for Alzheimer's Disease

Huperzine A As Potential Treatment Of Alzheimer'S Disease: An Assessment On Chemistry, Pharmacology, And Clinical Studies

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis

Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology

Evaluation of the in Vitro and in Vivo Metabolic Pathway and Cytochrome P450 Inhibition/induction Profile of Huperzine A.

[Clinical Efficacy and Safety of Huperzine Alpha in Treatment of Mild to Moderate Alzheimer Disease, a Placebo-Controlled, Double-Blind, Randomized Trial].

Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimer's Disease

Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews

Comparative clinical effectiveness of donepezil versus huperzine in elderly patients with mild cognitive impairment

Non-cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase

Huperzine A Ameliorates Cognitive Deficits In Streptozotocin-Induced Diabetic Rats

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review